Matuszak_2012_Eur.J.Pharm.Sci_45_263

Reference

Title : Dual inhibition of MAGL and type II topoisomerase by N-phenylmaleimides as a potential strategy to reduce neuroblastoma cell growth - Matuszak_2012_Eur.J.Pharm.Sci_45_263
Author(s) : Matuszak N , Hamtiaux L , Baldeyroux B , Muccioli GG , Poupaert JH , Lansiaux A , Lambert DM
Ref : Eur J Pharm Sci , 45 :263 , 2012
Abstract :

The endocannabinoid system is implicated in numerous physiopathological processes while more and more pieces of evidence wave the link between this complex machinery and cancer related phenomenon. In these lines, we confirmed the effects of 2-arachidonoylglycerol (2-AG), the main endocannabinoid, on neuroblastoma cells proliferation in vitro, and proved that some N-phenylmaleimide compounds that were previously shown as MAGL inhibitors can also inhibit type 2 topoisomerase. We also shed light on their antiproliferative effects on a neuroblastoma cell line. In order to establish a link between MAGL inhibition, topoisomerase inhibition and the effects on N1E-115 cells, we tested combinations of maleimides or known endocannabinoid metabolism inhibitors and 2-AG, the major MAGL substrate, on N1E-115 cells. However, none of the inhibitors tested, except the carbamate CAY10499, managed to increase 2-AG's effects. Even the MAGL reference inhibitor JZL184 failed to induce a stronger inhibition of proliferation.

PubMedSearch : Matuszak_2012_Eur.J.Pharm.Sci_45_263
PubMedID: 22127371

Related information

Inhibitor CAY10499

Citations formats

Matuszak N, Hamtiaux L, Baldeyroux B, Muccioli GG, Poupaert JH, Lansiaux A, Lambert DM (2012)
Dual inhibition of MAGL and type II topoisomerase by N-phenylmaleimides as a potential strategy to reduce neuroblastoma cell growth
Eur J Pharm Sci 45 :263

Matuszak N, Hamtiaux L, Baldeyroux B, Muccioli GG, Poupaert JH, Lansiaux A, Lambert DM (2012)
Eur J Pharm Sci 45 :263